Advantages:
- Blocks tumor signaling pathways to suppress cancer growth and spread effectively
- Resists enzymatic breakdown, enabling sustained and durable therapeutic activity
- Penetrates the brain and gut, supporting broader cancer treatment applications
- Delivers antibody level efficacy at potentially far lower manufacturing cost
Summary:
Cancer remains one of the most urgent challenges in medicine, and the epidermal growth factor receptor sits at the center of that fight. Abnormal EGFR expression drives tumor progression in lung, colon, and brain cancers, making it a critical target. Yet despite decades of research, no existing therapy has fully solved the problem of effectively intercepting this signaling pathway without serious tradeoffs in toxicity, resistance, or cost.
Current EGFR treatments force clinicians into difficult compromises. Small molecule inhibitors trigger resistance and toxic side effects, while monoclonal antibodies, though effective, carry prohibitive manufacturing costs. Natural peptides offer a cheaper path but break down too quickly in the body to sustain therapeutic impact. This macrocyclic peptidomimetic technology resolves all three limitations at once, delivering antibody like extracellular targeting, proven resistance to enzymatic degradation, and pharmacokinetic properties that suggest oral bioavailability and brain penetration potential.
Representative picture of beads for screening. The brightly red bead is the positive bead which was picked up manually.
Desired Partnerships:
- License
- Sponsored Research
- Co-Development